EPO and chronic kidney disease: The discovery of Epo led to the invention of erythropoiesis stimulating agents (ESAs) to treat anemic patients with chronic kidney disease (CKD) (Jacobs et al., 1985; Kalantar‐Zadeh, 2017; Miyake, Kung, & Goldwasser, 1977).